Novel UHRF1-MYC Axis in Acute Lymphoblastic Leukemia

Cancers (Basel). 2022 Aug 31;14(17):4262. doi: 10.3390/cancers14174262.

Abstract

Ubiquitin-like, containing PHD and RING finger domain, (UHRF) family members are overexpressed putative oncogenes in several cancer types. We evaluated the protein abundance of UHRF family members in acute leukemia. A marked overexpression of UHRF1 protein was observed in ALL compared with AML. An analysis of human leukemia transcriptomic datasets revealed concordant overexpression of UHRF1 in B-Cell and T-Cell ALL compared with CLL, AML, and CML. In-vitro studies demonstrated reduced cell viability with siRNA-mediated knockdown of UHRF1 in both B-ALL and T-ALL, associated with reduced c-Myc protein expression. Mechanistic studies indicated that UHRF1 directly interacts with c-Myc, enabling ALL expansion via the CDK4/6-phosphoRb axis. Our findings highlight a previously unknown role of UHRF1 in regulating c-Myc protein expression and implicate UHRF1 as a potential therapeutic target in ALL.

Keywords: UHRF1; acute lymphocytic leukemia; c-Myc.

Grants and funding

This work was supported by the generous philanthropic contributions to The University of Texas MD Anderson Cancer Center Moon Shots Program™.